Drug Profile
Research programme: G protein-coupled receptors in thrombosis - Actelion
Alternative Names: AX 109Latest Information Update: 27 Jun 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 12 Jun 2007 Discontinued - Preclinical for Thrombosis in Switzerland (unspecified route)
- 19 Nov 2003 Axovan has been acquired by Actelion Pharmaceuticals